Discover PT-141 dosage trends, reconstitution volumes, and vial size preferences from anonymized WPA peptide calculator sessions.
PT-141 (bremelanotide) is a melanocortin receptor agonist studied for its effects on sexual arousal and function in both sexes. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their PT-141 subcutaneous reconstitution protocol.
PT-141 (bremelanotide) is the cyclic heptapeptide melanocortin agonist developed by Palatin Technologies as a deliberate clinical refinement of Melanotan II — the same Hadley/Hruby alpha-MSH analog research program from the University of Arizona produced both molecules, but PT-141 was engineered to retain the MC4 receptor agonism that drives the sexual-arousal effect while substantially reducing the MC1-mediated melanin-synthesis (tanning) and skin-flushing side effects that limited MT-2's clinical viability. The Palatin program took bremelanotide through a long development arc — initial nasal formulation work was abandoned over blood-pressure spikes — and ultimately repositioned the molecule as a subcutaneous on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 (bremelanotide) is a melanocortin research peptide most often sourced for libido and sexual-function research. It is the same molecule sold as the FDA-approved drug Vyleesi, and ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Bremelanotide is a melanocortin-receptor agonist with selectivity for MC4R (and weaker activity at MC1R, MC3R, MC5R). MC4R activation in CNS nuclei involved in sexual response — including the medial preoptic area and the paraventricular nucleus — is thought to drive its pro-desire effect; unlike PDE-5 inhibitors, the mechanism is central rather than vascular.
Two pivotal Phase 3 trials (RECONNECT, Kingsberg et al., Obstet Gynecol 2019) randomized 1,202 premenopausal women with HSDD to subcutaneous bremelanotide 1.75mg or placebo and reported statistically significant improvements in desire and decreases in distress. The most common adverse events were nausea (40%), facial flushing, and transient blood-pressure elevation; the drug is contraindicated in uncontrolled hypertension and known cardiovascular disease.
PT-141 has a reported half-life of ~2.7 hours, and the dose intervals researchers model most often fall around as needed (max once per 24 h). Short half-life and as-needed dosing mean PT-141 does not build up — each dose acts on its own. It is taken ~45 minutes before activity, with no more than one dose in 24 hours. It is catalogued under Testosterone Peptides on WPA.
546 PT-141 reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (161 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (524 sessions). The most common dosing frequency is once weekly (31 logged protocols), followed by 2x/week (14).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.